Business Context and Reporting Period
This Form 8-K, filed by Brilliant Acquisition Corporation (the filing does not identify T3 Defense Inc. as the registrant), reports events occurring on or around October 17–19, 2022. Brilliant is a British Virgin Islands special purpose acquisition company (SPAC) pursuing a proposed business combination with Nukkleus, Inc.
Key Financial and Capitalization Information
- Brilliant issued Nukkleus an unsecured, non-interest-bearing promissory note with principal of $22,600. The note matures upon completion of the initial business combination.
- If no business combination is completed, repayment is limited to amounts remaining outside the trust account, if any.
- Note proceeds were deposited into the trust account in connection with extending the business-combination deadline.
- Shareholders redeemed 2,375,991 shares.
- Following redemptions and the additional deposit, the trust account held approximately $6.0 million, or approximately $10.64 per public share.
- Following the redemptions, 2,075,936 ordinary shares remained outstanding, including 1,511,000 shares held by initial shareholders that were not subject to redemption.
- The filing provides no revenue, operating profit, net income, cash-flow, margin, or broader debt metrics for the reporting period.
Material Changes Versus the Prior Position
- Shareholders approved extending the business-combination deadline from October 23, 2022, to no later than January 23, 2023.
- The deadline may be extended monthly without additional shareholder approval upon depositing $0.04 per public ordinary share.
- The amended and restated articles of association became effective upon filing with the British Virgin Islands General Registry on October 19, 2022.
- The transaction-related trust balance and public-share count declined materially as a result of the shareholder redemptions.
Outlook, Commentary, Risks, and Unusual Items
Brilliant announced a further one-month extension of its business-combination period to November 23, 2022, supported by the trust-account deposit. The proposed Nukkleus transaction remained subject to shareholder and regulatory approvals, satisfaction of transaction conditions, minimum trust-account requirements, and other closing conditions.
Key risks include failure to complete the transaction before the applicable deadline, failure to obtain further extensions, insufficient trust funds after redemptions, regulatory or shareholder approval issues, Nasdaq listing risks, litigation, market volatility, and risks associated with implementing post-combination business plans. The proposed transaction may not be completed.
Important Facts for Investors to Verify
- Confirm the correct registrant and transaction parties, because the supplied filing is for Brilliant Acquisition Corporation rather than T3 Defense Inc.
- Review the full $22,600 promissory note and its repayment priority if the business combination fails.
- Verify the final trust-account balance, redemption totals, and per-share trust value.
- Confirm whether the Nukkleus business combination satisfies all closing conditions and receives required approvals.
- Track the November 23, 2022 deadline and any subsequent monthly extensions or liquidation consequences.
- Review the related Form S-4, proxy statement/prospectus, and risk-factor disclosures before making an investment or voting decision.